Tuberculosis in patients with human immunodeficiency virus infection

New England Journal of Medicine

Volumn 340, Issue 5, 1999, Pages 367-

  Havlir, Diane V ^a   Barnes, Peter F ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; ETHAMBUTOL; INDINAVIR; ISONIAZID; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC PROPHYLAXIS; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; DRUG INDICATION; HIGH RISK PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT PLANNING;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DISEASE SUSCEPTIBILITY; HIV INFECTIONS; HUMANS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RIFAMPIN; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0344609266     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199902043400507     Document Type: Review

References (75)

1. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med 1997; 126:123-32.
2. Friedman LN, Williams MT, Singh TP, Frieden TR. Tuberculosis, AIDS, and death among substance abusers on welfare in New York City. N Engl J Med 1996;334:828-33.
3. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment - length polymorphisms. N Engl J Med 1992;326:231-5.
4. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-50.
5. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-44.
6. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996;335:1941-9.
7. Barnes PF, Modlin RL. Human cellular immune responses to Mycobacterium tuberculosis. Curr Top Microbiol Immunol 1996;215:197-219.
8. Zhang M, Gong J, Iyer DV, Jones BE, Modlin RL, Barnes PF. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 1994;94:2435-42.
9. Toossi Z, Nicolacakis K, Xia L, Ferrari NA, Rich EA. Activation of latent HIV-1 by Mycobacterium tuberculosis and its purified protein derivative in alveolar macrophages from HIV-infected individuals in vitro. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:325-31.
10. Goletti D, Weisman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996;157:1271-8.
11. Garrait V, Cadranel J, Esvant H, et al. Tuberculosis generates a microenvironment enhancing the productive infection of local lymphocytes by HIV. J Immunol 1997;159:2824-30.
12. Nakata K, Rom WN, Honda Y, et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997;155:996-1003.
13. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995;151:129-35.
14. Whalen C, Okwera A, Johnson J, et al. Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis: the Makerere University-Case Western Reserve University Research Collaboration. Am J Respir Crit Care Med 1996;153:1977-81.
15. Whalen C, Horsburgh CR Jr, Hom D, Lahart C, Simberkoff M, Ellner J. Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS 1997;11:455-60.
16. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR Morb Mortal Wkly Rep 1989;38:236-8, 243-50.
17. Katz DJ, Hall WN, Keon NB, Crane LR. HIV testing in patients with tuberculosis: physician response to national recommendations. Am Rev Respir Dis 1993;147:1283-6.
18. Asch SM, London AS, Barnes PF, Gelberg L. Testing for human immunodeficiency virus infection among tuberculosis patients in Los Angeles. Am J Respir Crit Care Med 1997;155:378-81.
19. Barnes PF, Silva C, Otaya M. Testing for human immunodeficiency virus infection in patients with tuberculosis. Am J Respir Crit Care Med 1996;153:1448-50.
20. Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993;148:1292-7.
21. Fee MJ, Oo MM, Gabayan AE, Radin DR, Barnes PF. Abdominal tuberculosis in patients infected with the human immunodeficiency virus. Clin Infect Dis 1995;20:938-44.
22. Dube M-P, Holtom PD, Larsen RA. Tuberculosis meningitis in patients with and without human immunodeficiency virus infection. Am J Med 1992;93;520-4.
23. Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression: the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 1997; 25:242-6.
24. Jones BE, Ryu R, Yang Z, et al. Chest radiographic findings in patients with tuberculosis with recent or remote infection. Am J Respir Crit Care Med 1997;156:1270-3.
25. Barnes PF. Rapid diagnostic tests for tuberculosis: progress but no gold standard. Am J Respir Crit Care Med 1997;155:1497-8. [Erratum, Am J Respir Crit Care Med 1997;156:1022.]
26. Rapid diagnostic tests for tuberculosis: what is the appropriate use? American Thoracic Society Workshop. Am J Respir Crit Care Med 1997; 155:1804-14.
27. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703-9.
28. Barnes PF, Yang Z, Preston-Martin S, et al. Patterns of tuberculosis transmission in central Los Angeles. JAMA 1997;278:1159-63.
29. Behr MA, Small PM. Molecular fingerprinting of Mycobacterium tuberculosis. how can it help the clinician? Clin Infect Dis 1997;25:806-10.
30. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-74.
31. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998;47(RR-20):1-58.
32. Brindle R, Nunn PP, Githui W, Allen BW, Gathua S, Waiyaki P. Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis 1993;147:958-61.
33. Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996;154:1034-8.
34. Perriëns JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995;332:779-84.
35. Pulido F, Pena J-M, Rubio R, et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997;157:227-32.
36. Hopewell PC. Tuberculosis in persons with human immunodeficiency virus infection: clinical and public health aspects. Semin Respir Crit Care Med 1997;18:471-84.
37. Jones BE, Otaya M, Antoniskis D, et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1994;150:1499-502.
38. Garay SM. Tuberculosis and HIV infection, Semin Respir Crit Care Med 1995;16:187-98.
39. Alwood K, Keruly J, Moore-Rice K, Stanton DL, Chaulk CP, Chaisson RE. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS 1994;8:1103-8.
40. Moore RD, Chaulk CP, Griffiths R, Cavalcante S, Chaisson RE. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996;154:1013-9.
41. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
42. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
43. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2:760-6.
44. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-45.
45. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuberc Lung Dis 1997;75:341-7.
46. Schwander S, Rusch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis: a single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuberc Lung Dis 1995;76:210-8.
47. McGregor MM, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996;154:1462-7.
48. Sun E, Heath-Chiozzi M, Cameron DW, et al. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse effects. In: Vol. 1 of Abstracts of the 11th International Conference on AIDS, Vancouver, B.C., July 7-12, 1996:18. abstract.
49. Thestrup-Pedersen K. Indinavir (MK 639) drug interaction studies. In: Vol. 1 of Abstracts of the 11th International Conference on AIDS, Vancouver, B.C., July 7-12, 1996:18. abstract.
50. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep 1996;45:921-5.
51. Cox SR, Herman BD, Botts DH, Carel BJ, Carberry PA. Delavirdine and rifabutin: pharmacokinetic evaluation in HIV-1 patients with concentration-targeting of delavirdine. In: Vol. 1 of Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998:144. abstract.
52. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-54.
53. Idem. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA panel. JAMA 1997;277:1962-9.
54. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong: the results up to 30 months. Am Rev Respir Dis 1977;115:727-35.
55. Doster B, Murray FJ, Newman R, Woolpert SF. Ethambutol in the initial treatment of pulmonary tuberculosis: U.S. Public Health Service tuberculosis therapy trials. Am Rev Respir Dis 1973;107:177-90.
56. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998;158:157-61.
57. Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin Infect Dis 1997;25:1465-7.
58. Lutfey M, Della-Latta P, Kapur V, et al. Independent origin of monorifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1996;153:837-40.
59. Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998;157: 1881-4.
60. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons - Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep 1991;40:585-91.
61. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City - turning the tide. N Engl J Med 1995;333:229-33.
62. Turett GS, Telzak EE, Torian LV, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995;21: 1238-44.
63. Park MM, Davis AL, Schluger NW, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983-1993: prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996;153:317-24.
64. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329:784-91. [Erratum, N Engl J Med 1993;329:1435.]
65. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995;332:336-7.
66. Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996;30:919-25.
67. Choudhri SH, Hawken M, Gathua S, et al. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin Infect Dis 1997;25:104-11.
68. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997;337:801-8.
69. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-92.
70. Gordin F, Chaisson R, Matts J, et al. A randomized trial of 2 months of rifampin and pyrazinamide versus 12 months of isoniazid for the prevention of tuberculosis in HIV-positive PPD+ patients. In: Vol. 1 of Programs and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998:223. abstract.
71. National action plan to combat multidrug-resistant tuberculosis: meeting the challenge of multidrug-resistant tuberculosis: summary of a conference: management of persons exposed to multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 1992;41(RR-11):1-71.
72. Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. MMWR Morb Mortal Wkly Rep 1991;40(RR-5):27-32.
73. Chin DP, Osmond D, Page-Shafer K, et al. Reliability of anergy skin testing in persons with HIV infection. Am J Respir Crit Care Med 1996; 153:1982-4.
74. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997;337:315-20.
75. Anergy skin testing and preventive therapy for HIV-infected persons: revised recommendations. MMWR Morb Mortal Wkly Rep 1997;46 (RR-15):1-10. [Erratum, MMWR Morb Mortal Wkly Rep 1997;46:800.]